- Home
- BODI vs ANL Comparison
BODI vs ANL Comparison
Compare BODI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BODI | ANL |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 62.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BODI | ANL |
|---|---|---|
| Price | $11.75 | $3.67 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 49.3K | ★ 1.3M |
| Earning Date | 11-10-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,565,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.38 | $0.88 |
| 52 Week High | $12.33 | $3.86 |
Technical Indicators
Market Signals| Indicator | BODI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 85.45 |
| Support Level | $10.03 | $1.63 |
| Resistance Level | $10.97 | $1.93 |
| Average True Range (ATR) | 0.77 | 0.32 |
| MACD | 0.10 | 0.22 |
| Stochastic Oscillator | 88.08 | 82.75 |
Price Performance
Historical ComparisonAbout BODI The Beachbody Company Inc.
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.